Get the Stockscreener App
14.60
1.18%
0.17
After Hours:
14.90
0.30
+2.05%
Theravance Biopharma Inc stock is traded at $14.60, with a volume of 447.80K.
It is up +1.18% in the last 24 hours and up +5.19% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$14.43
Open:
$14.36
24h Volume:
447.80K
Relative Volume:
1.21
Market Cap:
$735.27M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-15.87
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
+3.77%
1M Performance:
+5.19%
6M Performance:
+63.49%
1Y Performance:
+81.14%
1-Day Range:
$14.07
$14.87
1-Week Range:
$13.66
$14.87
52-Week Range:
$7.88
$14.87
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
14.60 | 726.71M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance Biopharma Inc. stock momentum explained2025 Short Interest & Daily Volume Surge Trade Alerts - newser.com
Relative strength of Theravance Biopharma Inc. in sector analysisGap Down & Free Long-Term Investment Growth Plans - newser.com
What insider purchases suggest about Theravance Biopharma Inc. (0TB) stockJuly 2025 Reactions & Free Reliable Trade Execution Plans - newser.com
Can swing trading help recover from Theravance Biopharma Inc. losses2025 Investor Takeaways & Weekly Momentum Picks - newser.com
How to manage a losing position in Theravance Biopharma Inc.Market Trend Report & Fast Momentum Stock Entry Tips - newser.com
Will Theravance Biopharma Inc. outperform the market2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
Theravance Biopharma Inc Stock Analysis and ForecastStock Rotation Strategies & Build Balanced Portfolio - earlytimes.in
Theravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month HighHere's What Happened - MarketBeat
Can Theravance Biopharma Inc. (0TB) stock hit consensus price targets2025 Institutional Moves & Long Hold Capital Preservation Plans - newser.com
Can Theravance Biopharma Inc. (0TB) stock double in coming yearsTrade Exit Summary & Verified Short-Term Plans - newser.com
Will Theravance Biopharma Inc. benefit from macro trendsPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Published on: 2025-09-29 07:43:32 - newser.com
What RSI levels show for Theravance Biopharma Inc. (0TB) stockBull Run & Free Safe Entry Trade Signal Reports - newser.com
Leading vs lagging indicators on Theravance Biopharma Inc. performanceJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - newser.com
Assenagon Asset Management S.A. Takes $264,000 Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
What analysts say about Theravance Biopharma Inc stockInstitutional Holding Changes & Ask Experts in Our Investment Forum - earlytimes.in
Is Theravance Biopharma Inc a good long term investmentBlue Chip Stock Analysis & Reinvest for Maximum Compounding Returns - earlytimes.in
Is Theravance Biopharma Inc. (0TB) stock positioned for secular growthQuarterly Trade Summary & Daily Volume Surge Trade Alerts - newser.com
Theravance Biopharma, Inc. Experiences Evaluation Revision Amid Mixed Market Signals - Markets Mojo
Volatility clustering patterns for Theravance Biopharma Inc.July 2025 WrapUp & Accurate Trade Setup Notifications - newser.com
Published on: 2025-09-22 08:51:34 - newser.com
Identifying reversal signals in Theravance Biopharma Inc.Day Trade & Real-Time Stock Price Movement Reports - newser.com
Analyzing net buyer seller activity in Theravance Biopharma Inc.Portfolio Performance Summary & Stepwise Trade Execution Plans - newser.com
Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to "Hold" at Zacks Research - MarketBeat
How Recent Developments Are Changing the Theravance Biopharma Investment Story - Yahoo Finance
Acadian Asset Management LLC Has $1.55 Million Stock Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update - MarketBeat
Aug Volume: Will Theravance Biopharma Inc stock benefit from M AMarket Sentiment Review & Expert Approved Momentum Ideas - خودرو بانک
Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year HighTime to Buy? - MarketBeat
Published on: 2025-09-19 20:47:30 - newser.com
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):